Skip to main content
. 2010 Aug 30;107(37):16268–16273. doi: 10.1073/pnas.1002696107

Fig. 4.

Fig. 4.

Recombinant IGF-1 treatment ameliorates Zmpste24-deficient mice progeroid phenotypes. (A) Representative photographs of 4-mo-old Zmpste24+/+ and Zmpste24−/− mice untreated and treated with recombinant human IGF-1. (B) Total body weight of 3-mo-old Zmpste24+/+ (n = 6), Zmpste24−/− (n = 8), and treated Zmpste24−/− (n = 8) mice. The treated mice exhibit a significant recovery of the total body weight. (C) Recombinant IGF-1 treatment restores GH levels of 4-mo-old Zmpste24−/− mice to those observed in their age-matched WT littermates. (D) Kaplan-Meier graph showing a significant increment of the maximum life span in IGF-1–treated Zmpste24−/− mice (diamonds; n = 8) compared with untreated mice (squares; n = 8). (E) Representative SDS/PAGE gel showing normal MUPs urine content in 4-mo-old Zmpste24−/− mice treated with recombinant IGF-1.